Payment overview · 2025
General Payments
$1,234.55
64 reported records · 18 companies
Healthcare provider profile · identity verified
James Edwin Tucker, DO
Allopathic & Osteopathic Physicians|Family Medicine · HANNIBAL, MO · NPI 1851772289
Verified facts
What the public records show
CMS Open Payments records show James Edwin Tucker, DO received $1,234.55 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.96 | 19.6% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $160.37 | 13.0% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.62 | 12.7% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $100.52 | 8.1% | 5 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $90.91 | 7.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.90 | 7.1% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $76.40 | 6.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $62.22 | 5.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.88 | 3.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.45 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.09 | 2.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.03 | 2.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.76 | 1.9% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $23.50 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.36 | 1.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.93 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.70 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.95 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,234.55 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $185.48 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $132.76 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $132.76 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $100.52 | 5 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $90.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.67 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $76.40 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.70 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.47 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.42 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $62.22 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 125 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 83 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
83 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 88 |
| Omeprazole | Omeprazole | 379 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 71 |
| Furosemide | Furosemide | 356 | 65 |
| Lisinopril | Lisinopril | 328 | 75 |
| Gabapentin | Gabapentin | 318 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 47 |
| Montelukast Sodium | Montelukast Sodium | 228 | 58 |
| Ozempic | Semaglutide | 222 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 52 |
| Losartan Potassium | Losartan Potassium | 178 | 48 |
| Tramadol Hcl | Tramadol Hcl | 174 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 166 | 35 |
| Celecoxib | Celecoxib | 164 | 51 |
| Potassium Chloride | Potassium Chloride | 161 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 37 |
| Metformin Hcl | Metformin Hcl | 158 | 31 |
| Prednisone | Prednisone | 154 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 142 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 20 |
| Metformin Hcl Er | Metformin Hcl | 138 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 35 |
| Sertraline Hcl | Sertraline Hcl | 135 | 33 |
| Clonazepam | Clonazepam | 129 | 21 |
| Eliquis | Apixaban | 125 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 40 |
| Lorazepam | Lorazepam | 119 | 30 |
| Famotidine | Famotidine | 117 | 20 |
| Meloxicam | Meloxicam | 117 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 25 |
| Memantine Hcl | Memantine Hcl | 104 | 11 |
| Carvedilol | Carvedilol | 103 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 28 |
| Jardiance | Empagliflozin | 94 | 15 |
| Bupropion Xl | Bupropion Hcl | 93 | 20 |
| Pregabalin | Pregabalin | 92 | 15 |
| Allopurinol | Allopurinol | 88 | 23 |
| Trazodone Hcl | Trazodone Hcl | 86 | 24 |
| Clonidine Hcl | Clonidine Hcl | 83 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 18 |
| Vraylar | Cariprazine Hcl | 83 | suppressed |
| Mounjaro | Tirzepatide | 70 | 12 |
| Donepezil Hcl | Donepezil Hcl | 68 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 17 |
| Spironolactone | Spironolactone | 65 | 14 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Finasteride | Finasteride | 63 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 19 |
| Carbamazepine | Carbamazepine | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 13 |
| Baclofen | Baclofen | 57 | 14 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Azithromycin | Azithromycin | 55 | 49 |
| Risperidone | Risperidone | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 12 |
| Carbamazepine Er | Carbamazepine | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 12 |
| Simvastatin | Simvastatin | 53 | 15 |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 12 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 15 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Topiramate | Topiramate | 43 | 14 |
| Diazepam | Diazepam | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Buspirone Hcl | Buspirone Hcl | 33 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 21 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Buprenorphine | Buprenorphine | 19 | suppressed |
| Dexamethasone | Dexamethasone | 19 | 19 |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Metolazone | Metolazone | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,234.55 · 64 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, DAYBUE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, GARDASIL 9, INGREZZA, Kerendia, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Senza, UBRELVY, VRAYLAR, WAKIX, Wegovy, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error